Surgery Partners financials
$14.41−1.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.31B | $3.11B | $2.74B | $2.54B | $2.23B | $1.86B | $1.83B | $1.77B | $1.34B | $1.15B |
| Gross profit | $3.31B | $3.11B | $2.74B | $2.54B | $2.23B | $1.86B | $1.83B | $1.77B | $1.34B | $1.15B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $397.0M | $369.9M | $328.2M | $339.7M | $286.7M | $176.2M | $231.6M | $97.0M | $170.3M | $205.6M |
| Net income | -$77.9M | -$168.1M | -$11.9M | -$54.6M | -$81.2M | -$155.6M | -$110.5M | -$238.1M | -$79.0M | $9.5M |
| Net margin | −2.4% | −5.4% | −0.4% | −2.2% | −3.6% | −8.4% | −6.0% | −13.4% | −5.9% | 0.8% |
| Diluted EPS | $-0.61 | $-1.33 | $-0.09 | $-0.59 | $-1.12 | $-3.19 | $-2.29 | $-4.96 | $-1.63 | $0.20 |
| EBITDA | $655.5M | $626.9M | $534.1M | $472.7M | $425.3M | $328.9M | $335.2M | $316.5M | $222.7M | $239.8M |
| Operating cash flow | $274.3M | $300.1M | $293.8M | $158.8M | $87.1M | $246.9M | $129.5M | $144.6M | $120.9M | $125.2M |
| Free cash flow | $195.6M | $209.7M | $205.0M | $78.2M | $29.5M | $204.0M | $55.9M | $104.8M | $91.3M | $86.1M |
| Diluted shares | 127.2M | 126.1M | 125.6M | 92.0M | 72.4M | 48.8M | 48.3M | 48.0M | 48.3M | 48.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $239.9M | $269.5M | $195.9M | $282.9M | $389.9M | $317.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $3.70B | $3.37B | $2.78B | $2.62B | $2.94B | $2.86B |
| Total assets | $8.12B | $7.89B | $6.88B | $6.68B | $6.12B | $5.41B |
| Total liabilities | $4.59B | $4.25B | $3.51B | $3.40B | $3.82B | $3.79B |
| Shareholders' equity | $3.13B | $3.20B | $3.03B | $2.94B | $1.97B | $882.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology